We are live on ! Find out more
NVS icon

Novartis

1,400 hedge funds and large institutions have $17.2B invested in Novartis in 2025 Q3 according to their latest regulatory filings, with 115 funds opening new positions, 476 increasing their positions, 481 reducing their positions, and 74 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more first-time investments, than exits

New positions opened: 115 | Existing positions closed: 74

6% more capital invested

Capital invested by funds: $16.2B → $17.2B (+$990M)

1% more funds holding

Funds holding: 1,3831,400 (+17)

0.02% more ownership

Funds ownership: 6.32%6.34% (+0.02%)

1% less repeat investments, than reductions

Existing positions increased: 476 | Existing positions reduced: 481

34% less call options, than puts

Call options by funds: $261M | Put options by funds: $398M

35% less funds holding in top 10

Funds holding in top 10: 1711 (-6)

Holders
1,400
Holders Change
+17
Holders Change %
+1.23%
% of All Funds
18.37%
Holding in Top 10
11
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-35.29%
% of All Funds
0.14%
New
115
Increased
476
Reduced
481
Closed
74
Calls
$261M
Puts
$398M
Net Calls
-$136M
Net Calls Change
-$74.7M
Name Holding Trade Value Shares
Change
Change in
Stake
EWA
126
Exencial Wealth Advisors
Oklahoma
$12.3M -$304K -2,492 -3%
AF
127
Allworth Financial
California
$12.3M -$31.8K -261 -0.3%
Fiera Capital (Canada)
128
Fiera Capital (Canada)
Quebec, Canada
$12M +$6.13M +50,263 +115%
AAIM
129
American Assets Investment Management
California
$12M
SA
130
Sanctuary Advisors
Indiana
$11.8M +$1.61M +13,155 +17%
EI
131
Ethic Inc
New York
$11.7M +$1.16M +9,507 +12%
ERP
132
Eldred Rock Partners
Texas
$11.6M +$1.2M +9,871 +12%
Manulife (Manufacturers Life Insurance)
133
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$11.5M -$91.8K -752 -0.8%
Carson Wealth (CWM LLC)
134
Carson Wealth (CWM LLC)
Nebraska
$11.5M +$832K +6,817 +8%
EPAM
135
Euro Pacific Asset Management
Puerto Rico
$11.4M -$158K -1,291 -1%
OCM
136
Osterweis Capital Management
California
$11.4M
MNA
137
Manning & Napier Advisors
New York
$11.3M -$907K -7,437 -8%
MGIA
138
Matthew Goff Investment Advisor
Texas
$11.3M -$58.8K -482 -0.5%
CFO
139
Callan Family Office
Pennsylvania
$11.3M +$113K +927 +1%
BG
140
Bahl & Gaynor
Ohio
$11.2M -$513K -4,208 -5%
ZAM
141
Zevin Asset Management
Massachusetts
$11.2M -$1.48M -12,129 -12%
LMIM
142
Lockheed Martin Investment Management
Maryland
$10.9M +$1.4M +11,500 +16%
BCWM
143
Bartlett & Co Wealth Management
Ohio
$10.9M -$136K -1,116 -1%
IHL
144
Investment House LLC
California
$10.5M +$24.4K +200 +0.2%
RMCM
145
Reynders McVeigh Capital Management
Massachusetts
$10.5M +$1M +8,214 +11%
UCFA
146
United Capital Financial Advisors
Texas
$10.4M +$550K +4,508 +6%
LOPW
147
Live Oak Private Wealth
North Carolina
$9.88M +$56.7K +465 +0.6%
GF
148
Gabelli Funds
New York
$9.86M -$305K -2,500 -3%
CCM
149
Cohen Capital Management
California
$9.82M -$79.3K -650 -0.8%
TBC
150
Tweedy, Browne Co
Connecticut
$9.75M -$148K -1,215 -2%

NVS Hedge Fund Activity: Q3 2025 in Review

1,400 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2025, worth a combined $17.2B — up 6.1% from $16.2B a quarter earlier.

Buyers outnumbered sellers: 115 funds opened new NVS positions and 74 closed out — a net gain of 41 holders — while 476 added to existing stakes and 481 trimmed.

The largest buyer was GQG Partners, adding an estimated $268M. The largest seller was Wellington Management Group, cutting an estimated $134M.

  • 1,400 institutional investors held Novartis (NVS) as of Q3 2025, up from 1,383 in Q2 2025.
  • Funds reported $17.2B of Novartis stock for Q3 2025, up 6.1% quarter-over-quarter.
  • 115 funds opened new Novartis positions in Q3 2025 and 74 closed out, a net change of +41 holders.
  • The largest Novartis buyer in Q3 2025 was GQG Partners, an estimated $268M added.
  • The largest Novartis seller in Q3 2025 was Wellington Management Group, an estimated $134M sold.

Based on aggregated 13F filings for Q3 2025.